Please login or register to print this page.

The British Journal
of Cardiology

This website is intended for healthcare professionals only

Early thrombolysis – the realities and the practicalities

September 2002 Volume 9, Supplement 7 Br J Cardiol 2002;9(Suppl 7):S1-S4

Sponsorship statement: This is a sponsored supplement to The British Journal of Cardiology. Details of sponsorship can be found by downloading the PDF.

The symposium Early thrombolysis – the realities and the practicalities which was an official satellite at the British Cardiac Society’s Annual Conference in Harrogate in May 2002 comes at an appropriate time. The government has recently announced that £14 million is to be made available for paramedic training, equipment for ambulances and thrombolytic drugs in England, in order to help achieve the targets set out in the National Service Framework (NSF) for Coronary Heart Disease (CHD). Also, the National Institute for Clinical Excellence (NICE) has made available its Appraisal Consultation Document for review by stakeholders. The document states that “patients with acute myocardial infarction in whom thrombolysis is indicated should receive thrombolytic treatment as soon as possible after the onset of symptoms”. This report reviews the symposium, which addressed many of the ‘nitty gritty’ aspects of optimising thrombolysis – the realities of lytic therapy administration by the ambulance service, experience from other countries and integrated care pathways in the UK. The following is an independent report, written by the British Journal of Cardiology editorial team and sponsored by an educational grant from Boehringer Ingelheim, who also organised the symposium.

In the near future, you will need to be a registered user to view full articles

Already a member? Login now

Disclaimer: UK prescribing information current at the date of publication of this supplement can be found by downloading the PDF. Medinews Cardiology Limited advises healthcare professionals to consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews Cardiology Limited cannot accept responsibility for any errors in prescribing which may occur.